CXR's REAL VALUE - 2016 or 2017?There is discussion out there about whether current markets are fairly priced. Many argue that stocks are cheap, by historical standards, and that they expect to see multiple expansion. 17 to 20 X earnings is not considered to be expensive. CXR is forecasted to experience earnings growth over the next few years of 6+%. Pharmaceuticals have often enjoyed higher multiples than the broader index. CXR has undergone a transformation and now only needs to create a track record. We just have to be patient. Fortunately, I believe that most market participants are just as impatient as all of us here, and hence are quick to forecast. If we experience multiple expansion, and wait for pharmaceuticals to come back into fashion, then we will be able to "clean up". I think that it is probably going to be as simple as that.